Galecto stockholders approve director elections, preferred stock conversion, and auditor ratification

Damora Therapeutics, Inc.

Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.
Preferred stock conversion approved: 226,407 for, 15,099 against, 800 abstain; 435,515 broker non-votes.
Ratification of EY as auditor approved: 660,974 for, 16,319 against, 528 abstain; no broker non-votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.